PBF 680

Drug Profile

PBF 680

Alternative Names: PBF-680

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Palobiofarma
  • Developer Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Palobiofarma
  • Class Antiasthmatics
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Phase II Asthma
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Spain (PO, Capsule)
  • 14 Sep 2015 Palobiofarma initiates enrolment in a phase II trial for Asthma in (EudraCT2015-001957-34)
  • 01 Dec 2014 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau & Palobiofarma complete a phase I trial in Healthy volunteers in Spain (NCT02208973)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top